VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to report positive results from the full data set of its Phase 2a Study evaluating NP-120 (“Ifenprodil”) for the potential treatment of idiopathic pulmonary…


Previous articleLooking Forward to Horizons Northwest, This September in Portland
Next articlePT352 – Alex Enchin & Ian-Michael Hébert, MA – HOLOS: Returning to Wholeness Through Nature and Community